AR052244A1 - Inhibidores de hmg co-a reductasa derivados de pirazol para el tratamiento de enfermedades relacionadas, un metodo para su preparacion y composiciones farmaceuticas que los contienen - Google Patents

Inhibidores de hmg co-a reductasa derivados de pirazol para el tratamiento de enfermedades relacionadas, un metodo para su preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
AR052244A1
AR052244A1 ARP050104871A ARP050104871A AR052244A1 AR 052244 A1 AR052244 A1 AR 052244A1 AR P050104871 A ARP050104871 A AR P050104871A AR P050104871 A ARP050104871 A AR P050104871A AR 052244 A1 AR052244 A1 AR 052244A1
Authority
AR
Argentina
Prior art keywords
aralkyl
aryl
alkyl
heteroaralkyl
heteroaryl
Prior art date
Application number
ARP050104871A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052244(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR052244A1 publication Critical patent/AR052244A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Compuestos y composiciones farmacéuticas utiles como agentes hipocolesterolémicos e hipolipidémicos. Más específicamente, se describen potentes inhibidores de la enzima 3-hidroxi-3-metilglutaril-coenzima A reductasa (ôHMG CoA reductasaö). Se describen también procedimientos de preparacion de tales compuestos y composiciones para tratar sujetos, incluyendo seres humanos, que sufren hiperlipidemia, hipercolesterolemia, hipertrigliceridemia, aterosclerosis, enfermedad de Alzheimer, hipertrofia prostática benigna (HPB), diabetes y osteoporosis. Reivindicacion 1: Un compuesto de formula (1), o una de sus sales, ésteres, amidas, hidratos, estereoisomeros o profármacos farmacéuticamente aceptables, o una sal farmacéuticamente aceptable del profármaco, en la que: R1 es hidrogeno, halogeno, alquilo C1-7, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R1 opcionalmente sustituido; R2 es hidrogeno, halogeno, alquilo C1-7, cicloalquilo C3-8, arilo, aralquilo, heteroarilo, heteroaralquilo, NC-, R2bR2aNCO(CH2)n-, R2bR2aNS(O)n-, R2cS(O)n-, R2bR2aN(CH2)n-, R2b-J-C(O)NR2a(CH2)n-, R2b-J-SO2NR2a(CH2) n-, R2b-J-SONR2a(CH2)n, R7OOC(CH2)n-, o R7CO(CH2)n-; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R2 opcionalmente sustituido; J es un enlace directo, O o N; cada uno de R2a y R2b es independientemente hidrogeno, alquilo C1-10, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R2a y R2b opcionalmente sustituido; o R2a y R2b tomados junto con el nitrogeno al que están unidos forman un anillo de 4-11 miembros que opcionalmente contiene al menos un heteroátomo adicional seleccionado de O, N y S, estando dicho anillo opcionalmente sustituido con al menos uno de arilo, aralquilo, heteroarilo, heteroaralquilo, alquilo C1-10, haloalquilo C1-10, cicloalquilo C3-8, halogeno, R7O-, R7OOC(CH2)n-, R7R8NCO(CH2)n-, R7O2S(CH2)n-, R8R7NSO2- o NC-; R2c es arilo, aralquilo, alquilo, heteroarilo o heteroaralquilo; estando el arilo, aralquilo, alquilo, heteroarilo o heteroaralquilo de R2c opcionalmente sustituido; cada uno de R7 y R8 es independientemente hidrogeno, alquilo C1-12, arilo o aralquilo; estando el alquilo, arilo o aralquilo de R7 y R8 opcionalmente sustituido; n es 0, 1 o 2; R3 es hidrogeno, alquilo C1-6, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R3 opcionalmente sustituido; y ôla línea de puntoö es un enlace o está ausente. Reivindicacion 12: Un compuesto de formula (2), o una de sus sales, ésteres, amidas, hidratos, estereoisomeros o profármacos farmacéuticamente aceptables, o una de las sales farmacéuticamente aceptables del profármaco, en la que: R1 es hidrogeno, halogeno, alquilo C1-7, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R1 opcionalmente sustituido; R2 es hidrogeno, halogeno, alquilo C1-7, cicloalquilo C3-8, arilo, aralquilo, heteroarilo, heteroaralquilo, NC-, R2bR2aNCO(CH2)n-, R2bR2aNS(O)n-, R2cS(O)n-, R2bR2aN(CH2)n-, R2b-J-C(O)NR2a(CH2)n-, R2b-J-SO2NR2a(CH2) n-, R2b-J-SONR2a(CH2)n, R7OOC(CH2)n-, o R7CO(CH2)n-; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R2 opcionalmente sustituido; J es un enlace directo, O o N; cada uno de R2a y R2b es independientemente hidrogeno, alquilo C1-10, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R2a y R2b opcionalmente sustituido; o R2a y R2b tomados junto con el nitrogeno al que están unidos forman un anillo de 4-11 miembros que opcionalmente contiene al menos un heteroátomo adicional seleccionado de O, N y S, estando dicho anillo opcionalmente sustituido con al menos uno de arilo, aralquilo, heteroarilo, heteroaralquilo, alquilo C1-10, cicloalquilo C3-8, halogeno, R7O- , R7OOC(CH2)n-, R7R8NCO(CH2)n-, R7O2S(CH2)n-, R8R7NSO2- o NC-; R2c es arilo, aralquilo, alquilo, heteroarilo o heteroaralquilo; estando el arilo, aralquilo, alquilo, heteroarilo o heteroaralquilo de R2c opcionalmente sustituido; cada uno de R7 y R8 es independientemente hidrogeno, alquilo C1-12, arilo o aralquilo; estando el alquilo, arilo o aralquilo de R7 y R8 opcionalmente sustituido; n es 0, 1 o 2; R3 es hidrogeno, alquilo C1-6, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R3 opcionalmente sustituido; y ôla línea de puntoö es un enlace o está ausente. Reivindicacion 14: Un compuesto de formula (3), o una de sus sales, ésteres, amidas, hidratos, estereoisomeros o profármacos farmacéuticamente aceptables, o una de las sales farmacéuticamente aceptables del profármaco, en la que: R1 es hidrogeno, halogeno, alquilo C1-7, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R1 opcionalmente sustituido; R2 es hidrogeno, halogeno, alquilo C1-7, cicloalquilo C3-8, arilo, aralquilo, heteroarilo, heteroaralquilo, NC-, R2bR2aNCO(CH2)n-, R2bR2aNS(O)n-, R2cS(O)n-, R2bR2aN(CH2)n-, R2b-J-C(O)NR2a(CH2)n-, R2b-J-SO2NR2a(CH2) n-, R2b-J-SONR2a(CH2)n, R7OOC(CH2)n-, o R7CO(CH2)n-; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R2 opcionalmente sustituido; J es un enlace directo, O o N; cada uno de R2a y R2b es independientemente hidrogeno, alquilo C1-10, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R2a y R2b opcionalmente sustituido; o R2a y R2b tomados junto con el nitrogeno al que están unidos forman un anillo de 4-11 miembros que opcionalmente contiene al menos un heteroátomo adicional seleccionado de O, N y S, estando dicho anillo opcionalmente sustituido con al menos uno de arilo, aralquilo, heteroarilo, heteroaralquilo, alquilo C1-10, cicloalquilo C3-8, halogeno, R7O-, R7OOC(CH2)n-, R7R8NCO(CH2)n-, R7O2S(CH2)n-, R8R7NSO2- o NC-; R2c es arilo, aralquilo, alquilo, heteroarilo o heteroaralquilo; estando el arilo, aralquilo, alquilo, heteroarilo o heteroaralquilo de R2c opcionalmente sustituido; cada uno de R7 y R8 es independientemente hidrogeno, alquilo C1- 12, arilo o aralquilo; estando el alquilo, arilo o aralquilo de R7 y R8 opcionalmente sustituido; n es 0, 1 o 2; R3 es hidrogeno, alquilo C1-6, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R3 opcionalmente sustituido; y ôla línea de puntoö es un enlace o está ausente. Reivindicacion 20: Un compuesto de formula (4), en la que: R1 es hidrogeno, halogeno, alquilo C1-7, cicloalquilo C3- 8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R1 opcionalmente sustituido; cada uno de R2a y R2b es independientemente hidrogeno, alquilo C1-10, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R2a y R2b opcionalmente sustituido; o R2a y R2b tomados junto con el nitrogeno al que están unidos forman un anillo de 4-11 miembros que opcionalmente contiene al menos un heteroátomo adicional seleccionado de O, N y S, estando dicho anillo opcionalmente sustituido con al menos uno de arilo, aralquilo, heteroarilo, heteroaralquilo, alquilo C1-10, cicloalquilo C3-8, halogeno, R7O-, R7OOC(CH2)n-, R7R8NCO(CH2)n-, R7O2S(CH2)n-, R8R7NSO2- o NC-; cada uno de R7 y R8 es independientemente hidrogeno, alquilo C1-12, arilo o aralquilo; estando el alquilo, arilo o aralquilo de R7 y R8 opcionalmente sustituido; n es 0, 1 o 2; R3 es hidrogeno, alquilo C1-6, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R3 opcionalmente sustituido. Reivindicacion 21: Un compuesto de formula (5), en la que: R1 es hidrogeno, halogeno, alquilo C1-7, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R1 opcionalmente sustituido; cada uno de R2a y R2b es independientemente hidrogeno, alquilo C1-10, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R2a y R2b opcionalmente sustituido; o R2a y R2b tomados junto con el nitrogeno al que están unidos forman un anillo de 4-11 miembros que opcionalmente contiene al menos un heteroátomo adicional seleccionado de O, N y S, estando dicho anillo opcionalmente sustituido con al menos uno de arilo, aralquilo, heteroarilo, heteroaralquilo, alquilo C1-10, cicloalquilo C3-8, halogeno, R7O-, R7OOC(CH2)n-, R7R8NCO(CH2)n-, R7O2S(CH2)n-, R8R7NSO2- o NC-; cada uno de R7 y R8 es independientemente hidrogeno, alquilo C1-12, arilo o aralquilo; estando el alquilo, arilo o aralquilo de R7 y R8 opcionalmente sustituido; n es 0, 1 o 2; R3 es hidrogeno, alquilo C1-6, cicloalquilo C3-8, arilo, aralquilo, heteroarilo o heteroaralquilo; estando el alquilo, cicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo de R3 opcionalmente sustituido; y X es anion F, Cl, Br o I. Reivindicacion 26: Un procedimiento que comprende las etapas de: a) hacer reaccionar un compuesto hidroxilado de formula (6), en condiciones suficientes par formar un compuesto de formula (7); b) hacer reaccionar un compuesto de formula (7), en condiciones suficientes para formar un compuesto de formula (8); c
ARP050104871A 2004-11-23 2005-11-21 Inhibidores de hmg co-a reductasa derivados de pirazol para el tratamiento de enfermedades relacionadas, un metodo para su preparacion y composiciones farmaceuticas que los contienen AR052244A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63048104P 2004-11-23 2004-11-23

Publications (1)

Publication Number Publication Date
AR052244A1 true AR052244A1 (es) 2007-03-07

Family

ID=35708411

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104871A AR052244A1 (es) 2004-11-23 2005-11-21 Inhibidores de hmg co-a reductasa derivados de pirazol para el tratamiento de enfermedades relacionadas, un metodo para su preparacion y composiciones farmaceuticas que los contienen

Country Status (25)

Country Link
US (2) US7446121B2 (es)
EP (1) EP1819681B1 (es)
JP (1) JP2008520642A (es)
KR (1) KR20070084455A (es)
AP (1) AP2007003979A0 (es)
AR (1) AR052244A1 (es)
AT (1) ATE439347T1 (es)
AU (1) AU2005308575A1 (es)
BR (1) BRPI0518300A2 (es)
CA (1) CA2590533C (es)
CR (1) CR9102A (es)
DE (1) DE602005016009D1 (es)
EA (1) EA200700875A1 (es)
ES (1) ES2328384T3 (es)
GT (1) GT200500338A (es)
IL (1) IL182569A0 (es)
MA (1) MA30108B1 (es)
MX (1) MX2007005137A (es)
NL (1) NL1030487C2 (es)
PA (1) PA8653401A1 (es)
PE (1) PE20061057A1 (es)
TN (1) TNSN07202A1 (es)
TW (1) TW200626556A (es)
UY (1) UY29220A1 (es)
WO (1) WO2006056845A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
WO2006087630A2 (en) * 2005-02-16 2006-08-24 Warner-Lambert Company Llc OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
US7834050B2 (en) * 2006-03-29 2010-11-16 Duke University Small molecule insulin mimetics absent quinones
WO2008059372A2 (en) * 2006-11-17 2008-05-22 Pfizer Products Inc. Crystal form of (3r,5r)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-metyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt
US9545105B2 (en) * 2010-10-21 2017-01-17 Bayer Intellectual Property Gmbh 1-(heterocyclic carbonyl) piperidines
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
CA2856196C (en) 2011-12-06 2020-09-01 Masco Corporation Of Indiana Ozone distribution in a faucet
CN108463437B (zh) 2015-12-21 2022-07-08 德尔塔阀门公司 包括消毒装置的流体输送系统
WO2019194207A1 (ja) * 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
CN114425329B (zh) * 2022-03-10 2024-04-19 西安凯立新材料股份有限公司 孕烯醇酮醋酸酯合成用催化剂及其制备方法和应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (de) 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3262977A (en) 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
BE637389A (es) 1962-09-13
US3857952A (en) 1967-12-22 1974-12-31 May & Baker Ltd Certain benzene derivatives useful in treating cardiac disorders
CH507249A (de) 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
BE795735A (fr) 1972-03-06 1973-06-18 Cerm Cent Europ Rech Mauvernay Nouvelles ethylenediamines substituees a activite cardiovasculaire
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
JPS608117B2 (ja) 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
DE2719912C3 (de) 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen
DE2733747C2 (de) 1977-07-27 1979-09-27 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CA1147342A (en) 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
JPS5953920B2 (ja) 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS559058A (en) 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
ES8207217A1 (es) 1980-10-09 1982-09-01 Hoechst Ag Procedimiento para la preparacion de un inactivador de alfa-amilasa
DE3166093D1 (en) 1981-01-05 1984-10-18 Takeda Chemical Industries Ltd N-substituted pseudo-aminosugars, their production and use
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4567175A (en) 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DK520784A (da) 1984-01-21 1985-07-22 Hoechst Ag Cycliske polypeptider, deres fremstilling og anvendelse
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
KR890001651B1 (ko) 1984-06-22 1989-05-12 산도즈 파마슈티칼스 코포레이션 메발로노락톤의 피라졸 동족체 및 이의 유도체의 제조방법
US4631286A (en) 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4634765A (en) 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4808621A (en) 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4957971A (en) 1986-07-07 1990-09-18 Warner-Lambert Company Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
EP0260066B1 (en) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5192772A (en) 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
EP0344383A1 (en) 1988-06-02 1989-12-06 Merrell Dow Pharmaceuticals Inc. Novel alpha-Glucosidase inhibitors
DE3836675A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Glykosidase-inhibitor salbostatin, verfahren zu seiner herstellung und seine verwendung
DE3918364A1 (de) 1989-06-06 1990-12-13 Hoechst Ag 3-desmethyl-2-methyl-mevalonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
US5185351A (en) 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5504078A (en) 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
JPH054943A (ja) 1990-08-30 1993-01-14 Sagami Chem Res Center 光学活性β，δ−ジケト酸エステル及びその還元体
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
CA2098167C (en) 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
SK158394A3 (en) 1992-06-26 1995-05-10 Pfizer Steroidal glycosides
US5284971A (en) 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
ATE159515T1 (de) 1992-07-21 1997-11-15 Ciba Geigy Ag Oxamidsäure-derivate als hypocholesterämische mittel
KR950703539A (ko) 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
DE4243279A1 (de) 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
CA2128044C (en) 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
JPH08143457A (ja) 1994-11-21 1996-06-04 Microbial Chem Res Found 酵素阻害剤および高脂血症抑制剤
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
PL193479B1 (pl) 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
JPH09173638A (ja) * 1995-12-25 1997-07-08 Hudson Soft Co Ltd 相対時間による派生シナリオ起動方法
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
TW506836B (en) 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
JPH10310578A (ja) * 1996-11-13 1998-11-24 Yoshitomi Pharmaceut Ind Ltd ３−フェニルピラゾール化合物
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
EP1048653B1 (en) 1997-12-05 2004-03-03 Eisai Co., Ltd. Donepezil polycrystals and process for producing the same
PA8471201A1 (es) 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DK1086706T3 (da) 1999-03-31 2004-03-08 Eisai Co Ltd Stabiliserede sammensætninger indeholdende nootropiske lægemidler
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6476057B1 (en) 1999-09-23 2002-11-05 G.D. Searle & Co. Use of substituted N, N-disubstituted cycloalkyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
US6683113B2 (en) 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US20030171377A1 (en) 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2004048334A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Phenyl substituted piperidine compounds for use as ppar activators
CA2509688A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
KR20060133013A (ko) * 2004-04-16 2006-12-22 워너-램버트 캄파니 엘엘씨 신규 이미다졸
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia

Also Published As

Publication number Publication date
EP1819681B1 (en) 2009-08-12
UY29220A1 (es) 2006-06-30
PA8653401A1 (es) 2006-09-08
US20060111422A1 (en) 2006-05-25
WO2006056845A1 (en) 2006-06-01
EP1819681A1 (en) 2007-08-22
CA2590533A1 (en) 2006-06-01
BRPI0518300A2 (pt) 2008-11-11
ES2328384T3 (es) 2009-11-12
DE602005016009D1 (de) 2009-09-24
MX2007005137A (es) 2007-06-22
MA30108B1 (fr) 2009-01-02
CR9102A (es) 2007-05-30
EA200700875A1 (ru) 2007-12-28
CA2590533C (en) 2010-09-07
IL182569A0 (en) 2007-07-24
US20090170852A1 (en) 2009-07-02
GT200500338A (es) 2006-06-22
KR20070084455A (ko) 2007-08-24
AP2007003979A0 (en) 2007-06-30
NL1030487C2 (nl) 2007-01-08
NL1030487A1 (nl) 2006-05-24
US7446121B2 (en) 2008-11-04
TNSN07202A1 (fr) 2008-11-21
TW200626556A (en) 2006-08-01
ATE439347T1 (de) 2009-08-15
AU2005308575A1 (en) 2006-06-01
JP2008520642A (ja) 2008-06-19
PE20061057A1 (es) 2006-11-09

Similar Documents

Publication Publication Date Title
AR052244A1 (es) Inhibidores de hmg co-a reductasa derivados de pirazol para el tratamiento de enfermedades relacionadas, un metodo para su preparacion y composiciones farmaceuticas que los contienen
RU2007147346A (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
ES2971710T3 (es) Procesos para la preparación de (S)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
Sirijindalert et al. Novel synthetic route to 1, 4-dihydropyridines from β-amino acrylates by using titanium (IV) chloride under facile conditions
CY1116119T1 (el) Παραγωγα ισοξαζολο-πυριδινης
EA201391158A1 (ru) Диаминиевые соли фенотиазина и их применение
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
DK1033364T3 (da) Cyanholdige oxamidsyrer og -derivater som thyroideareceptorligander
NO20084302L (no) 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer
PE20091444A1 (es) Derivados de isoxazolo-pirazina
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
IL183663A0 (en) Process for the preparation of a 2-ethylaminopyridine derivative
RU2007147340A (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
MA30315B1 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2010149496A (ru) Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
ATE243679T1 (de) Neuroprotektive 3-(piperidinyl-1)-chroman-4,7- diol und 1-(4-hyphoxyphenyl)-2-(piperidinyl-1)- alkanolderivate
PE20060184A1 (es) Derivados de imidazoles como inhibidores de la sintesis del colesterol
WO2007038387A3 (en) Compounds and methods for the treatment of viruses and cancer
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
NO20076000L (no) Aminosyrederivater
DE602006019710D1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
AR064421A1 (es) Sintesis mejorada para la preparacion del acido[r-(r*,r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirrol-1-heptanoico o una sal farmaceuticamente aceptable del mismo,asi como de intermediarios usados en el procedimiento.
DK1466905T3 (da) Fremgangsmåde til fremstilling af en optisk aktiv oxoheptensyreester

Legal Events

Date Code Title Description
FB Suspension of granting procedure